The actual amount of Corporate VC investment is hard to find. Fair to say that it is some healthy fraction of the $37B in 2017.
Corporate venture capital and private venture capital are being used as bellwethers of the state of the startup ecosystem. The primary message of this presentation is that corporate/startup collaboration goes well beyond corporate venture capital. In fact, it is just one element of a much more complex phenomenon.
National Science Foundation data on average annual R&D spend for 2014-2015. This is CORPORATE R&D. It does NOT include government or university research spend.
I have gotten some grief for this slide so its important to be clear about what it is and what is not. First, it is NOT an attempt to precisely equate venture capital with corporate R&D spending. However, It IS an attempt to compare the level of money (fuel) pursuing each objective because they are both aimed at growth. It is also true that about 70% of all startup exits are to corporate M&A – so it mostly ends up in the same place as a growth driver for large businesses.
If you are in the software business, you are swimming in an endless sea of startups and FOMO runs high. If you are in healthcare, there is a lot going on, especially in pharma/biopharma and med tech. If you are in hardware, consumer products, energy or media, it drops off quite a bit.
The inside-in case is an important part of strategic innovation but is not co-creation and is not within the scope of this particular presentation.